Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension

Lung

Volumn 186, Issue 3, 2008, Pages 151-156

  Zamarrón, Carlos ^a   Ricoy, Jorge ^a   Riveiro, Alberto ^a   Gude, Francisco ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Cardiovascular diseases; Fibrinolysis; Hypertension; Plasminogen activator inhibitor 1; Sleep apnea syndrome

Indexed keywords

CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SLEEP APNEA SYNDROME; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; DISEASE PROGRESSION; ELECTROENCEPHALOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYSOMNOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE;

EID: 44549083893     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-008-9076-8     Document Type: Article

References (37)

1. Remmers JE, deGroot WJ, Sauerland EK, Anch AM (1978) Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 44:931-938
2. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230-1235
3. Pichel F, Zamarron C, Magán F, del Campo F, Alfarez-Sala R, Suarez JR (2004) Health-related quality of life in patients with obstructive sleep apnea: effects of long-term positive airway pressure treatment. Respir Med 98:968-976
4. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J (1999) The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 340:847-851
5. Coccagna G, Pollini A, Provini F (2006) Cardiovascular disorders and obstructive sleep apnea syndrome. Clin Exp Hypertens 28:217-224
6. Lavie L (2005) Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 23:1059-1075
7. Suzuki YJ, Jain V, Park AM, Day RM (2006) Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med 40:1683-1692
8. Schulz R (2005) The vascular micromilieu in obstructive sleep apnoea. Eur Respir J 25:780-782
9. Juhan-Vague I, Alessi MC, Vague P (1996) Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28:371-380
10. Saigo M, Hsue PY, Waters DD (2004) Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 46:524-538
11. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padró T (2006) Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 6:439-456
12. Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H (2000) Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 162:2039-2042
13. Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W (2000) Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 16:648-652
14. Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M (2002) In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 69:229-234
15. Hui DS, Ko FW, Fok JP, Chan MC, Li TS, Tomlinson B, Cheng G (2004) The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125:1768-1775
16. Guardiola JJ, Matheson PJ, Clavijo LC, Wilson MA, Fletcher EC (2001) Hypercoagulability in patients with obstructive sleep apnea. Sleep Med 2:517-523
17. Von Kanel R, Dimsdale JE (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124:1956-1967
18. Chmielewska J, Ranby M, Wiman B (1983) Evidence for a rapid inhibitor to tPA in plasma. Thromb Res 31:427-436
19. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561
20. Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Anglès-Cano E, Lijnen HR (2006) Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4:664-670
21. Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, Fujii S, Tsutsui H, Tamaki N (2007) Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J 71:348-353
22. Von Känel R, Loredo JS, Ancoli-Israel S, Dimsdale JE (2007) Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 131:733-739
23. Mannucci PM, Gringeri A, Peyvandi F, Di Paolantonio T, Mariani G (2002) Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thromb Haemost 87:342-343
24. Toff WD, Jones CI, Ford I, Pearse RJ, Watson HG, Watt SJ, Ross JA, Gradwell DR, Batchelor AJ, Abrams KR, Jeijers JC, Goodall AH, Greaves M (2006) Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. JAMA 295:2251-2261
25. Gertler JP, Weibe DA, Ocasio VH, Abbott WM (1991) Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vasc Surg 13:428-433
26. Liao H, Hyman MC, Lawrence DA, Pinsky DJ (2007) Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 21:935-949
27. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K (1995) Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 18:188-194
28. Barcelo A, Llompart E, Barbe F, Morlá M, Vila M, Agusti AG (2002) Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea. Respir Med 96:193-196
29. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague J (1994) Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 72:44-53
30. Venugopal B, Sharon R, Abramovitz R, Khasin A, Miskin R (2001) Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction alter injecting mice with kainate or adrenergic agents. Cardiovasc Res 49:476-483
31. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG (2006) Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 100:343-348
32. Von Kanel R, Loredo JS, Ancoli-Israel S, Dimsdale JE (2006) Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 10:139-146
33. Shatos MA, Doherty JM, Stump DC, Thompson EA, Collen D (1990) Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture. J Biol Chem 265:20443-20448
34. Juhan-Vague I, Alessi MC, Mavri A, Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579
35. Mertens I, Van der Planken M, Corthouts B, Van Gaal LF (2001) Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33:602-607
36. Sundell IB, Dahlen GH, Ranby M (1991) Diet-induced changes in glucose and triglycerides are associated with changes in plasminogen activator inhibitor levels. Haemostasis 21:175-180
37. Fogari R, Zoppi A (2006) Antihypertensive drugs and fibrinolytic function. Am J Hypertens 19:1293-1299